Advertisement

Lung Cancer | Tumor

CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.

FDA Approval From Winter 2023 You May Have Missed

March 21st 2023

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Robin Roberts Provides an Update on Her Partner’s Cancer, EPA Recommends Limit to Cancer-Causing Chemicals in Water and More

March 17th 2023

From Robin Roberts providing an update on her partner, Amber Laign’s “rough year” with breast cancer, to Kathy Griffin’s suspected cause of lung cancer, here’s what’s happening in the oncology space this week.

Imfinzi-Based Treatment Before, After Surgery May Significantly Improve Survival in Resectable NSCLC

March 11th 2023

Patients with resectable non-small cell lung cancer treated with Imfinzi plus chemo before surgery or as monotherapy after surgery demonstrated significant improvements to event-free survival compared with those treated with neoadjuvant chemotherapy and surgery, study results show.

Keytruda Meets Trial Goals for Non-Small Cell Lung Cancer Treatment

March 9th 2023

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

TKI Drug Plus Chemotherapy May Improve Lung Cancer Outcomes

March 3rd 2023

Gefitinib plus chemotherapy could be considered a first-line treatment option for patients with EGFR-mutated NSCLC with brain metastases.

Trial of Plinabulin, Keytruda, Docetaxel Kicks Off in Lung Cancer

March 1st 2023

The first patient was enrolled in a three-drug clinical trial, which researchers hope will lend insight into immunotherapy resistance in lung cancer.

Keytruda Misses Outcomes in Two Clinical Trials

March 1st 2023

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

Why Patients with Lung Cancer Should Broaden Their Horizon

February 24th 2023

As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about networking during a lung cancer diagnosis.

Understanding Supportive Services in Lung Cancer

February 24th 2023

As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about supportive services for lung cancer.

Advocating for Biomarker Testing During a Lung Cancer Diagnosis

February 24th 2023

As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about what biomarker testing is and why patients with lung cancer should advocate for themselves during that process.

Don’t Sneak Around a Second Opinion During Lung Cancer

February 24th 2023

As a part of its Speaking Out Video series, CURE® spoke with Terri Conneran, on behalf of KRAS Kickers, about the importance of second opinions during a lung cancer diagnosis.

Who Will Win the Race of Cancer?

February 24th 2023

I’m in the race of cancer, hoping that a cure will pass the finish line before I do.

I Wish I Was Told Everything That May Happen While Undergoing Cancer Treatment

February 20th 2023

Chemotherapy affected my brain in ways that I was never told about.

Targeted Therapies for Lung Cancer Are Underused in Patients on Medicaid

February 9th 2023

Some patients with metastatic non-small cell lung cancer are not receiving effective therapies for their disease, the study authors suggested.

Keytruda Approval Offers ‘Another Form of Insurance’ to Keep Lung Cancer From Returning

February 8th 2023

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

Physical Function May Decline in Women After Cancer Diagnosis, Throughout Survivorship

February 7th 2023

Postmenopausal women cancer survivors, including lung, breast, colorectal and endometrial cancer, may have a greater physical function decline than is generally expected at their age, which may lead to lower quality of life after treatment.

Despite Rapid Increase in Immunotherapy Use for Lung Cancer, Survival Benefit for Older Patients Is Modest

February 2nd 2023

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

Trial to Investigate If Novel Drug Combo Can Boost Outcomes in Lung Cancer

January 31st 2023

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

Trial to Investigate Novel Drug in KRAS-Mutant Lung Cancer

January 27th 2023

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

FDA Approves Post-Surgical Keytruda for Lung Cancer Subset

January 26th 2023

The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer.

Iadademstat-Placebo Combo to Be Studied in Neuroendocrine Cancers

January 26th 2023

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.

Immunotherapy Plus Chemo Boosts Event-Free Survival in Resectable Lung Cancer

January 18th 2023

Patients with operable non-small cell lung cancer who were treated with an anti-PD-1 monoclonal antibody plus a doublet chemotherapy regiment did not experience cancer recurrence or new symptom onset during follow-up in a recent study.

New KRAS Inhibitor to Be Studied in Lung, Colon and Pancreatic Cancers

January 18th 2023

The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.

Creating an Advocacy Group at the Onset of a Global Pandemic: KRAS Kickers Founder Shares Her Story

December 29th 2022

Lung cancer survivor Terri Conneran shares her story of creating a non-profit to help connect with fellow patients and survivors who have the KRAS biomarker.

FDA’s Approval of Krazati Demonstrates ‘Watershed Moment’ for Treatment of NSCLC With Genetic Mutation

December 21st 2022

An expert explains what the FDA’s accelerated approval of Krazati means for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer and what he hopes will come next.

FDA Expands Indication for Pemfexy to Include Subset of Advanced Non-Small Cell Lung Cancer

December 19th 2022

The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.

20 Years of Cancer Care Advancements

December 15th 2022

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

FDA Approves Krazati for KRAS G12C-Mutant Lung Cancer

December 13th 2022

Krazati was granted an accelerated approval for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer, according to the Food and Drug Administration.

Evaluating Existing and Future Surgical Options for Early-Stage Lung Cancer

November 23rd 2022

As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed how far the space has come with surgical advances, and where it is headed, in treating early-stage lung cancer.

‘Time is of the Essence’ in Decision-Making for Early-Stage Lung Cancer

November 23rd 2022

As part of its “Speaking Out” video series, Dr. Peter Baik, on behalf of Cancer Treatment Centers of America, discussed the importance of timing and decision-making of treatment in early-stage lung cancer.

NEXT PAGE
PREVIOUS PAGE
Advertisement
Advertisement